Actemra, Long-Term Special Drug Use Surveillance in Takayasu arteritis and Giant cell arteritis patients - Actemra, Long-Term Special Drug Use Surveillance in TAK/GCA patients

GCA Of the 117 patients 38.5% reported adverse events The most common adverse events of special interest were neutropaenia and leukopaenia 7.7% followed by serious infection 6.0% The relapse-free proportion was 85.0%; relapse after remission 6.0% and no remission 9.0% At the last observation, 94.2% of relapse-free patients received a concomitant glucocorticoid dose of under 10 mg per day Fatigue headache neck pain and absence of LVLs were positively associated with the relapse etc